alexa Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19.
Immunology

Immunology

Lupus: Open Access

Author(s): Timm R, Kaiser R, Ltsch J, Heider U, Sezer O, , Timm R, Kaiser R, Ltsch J, Heider U, Sezer O,

Abstract Share this page

Abstract Cyclophosphamide (CP), a widely used cytostatic, is metabolized by polymorphic drug metabolizing enzymes particularly cytochrome P450 (CYP) enzymes. Its side effects and clinical efficacy exhibit a broad interindividual variability, which might be due to differences in pharmacokinetics. CP-kinetics were determined in 60 patients using a global and a population pharmacokinetic model considering functionally relevant polymorphisms of CYP2B6, CYP2C9, CYP2C19, CYP3A5, and GSTA1. Moreover, metabolic ratios were calculated for selected CP metabolites, analyzed by (31)P-NMR-spectroscopy. Analysis of variance revealed that the CYP2C19*2 genotype influenced significantly pharmacokinetics of CP at doses
  • DOI: 10.1038/sj.tpj.6500330
  • This article was published in Pharmacogenomics J and referenced in Lupus: Open Access

    Relevant Expert PPTs

    Relevant Speaker PPTs

    Peer Reviewed Journals
     
    Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
    International Conferences 2017-18
     
    Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

    Contact Us

     
    © 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
    adwords